A phase 2 trial suggests that frontline osimertinib and platinum-based chemotherapy is safe and effective in EGFR-mutated, advanced NSCLC.
Jen Smith
Jen Smith is the medical editor of Cancer Therapy Advisor. She was previously the editor of Hematology Times and the oncology editor for MDedge Hematology/Oncology. She has a BS in journalism.
